***Background.*** Isavuconazole (ISA) is a novel broad-spectrum triazole antifungal available as a water-soluble prodrug in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial assessed the efficacy and safety of ISA vs voriconazole (VRC) in patients with IMD. Here we report outcomes in a pre-specified subset of patients from this non-inferiority trial, who had proven, probable, or possible pulmonary mold disease (PMD) without other site involvement (lower respiratory tract disease only).

***Methods.*** Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. Eligibility criteria and pre-specified outcomes are available at clinicaltrials.gov, NCT00412893. The primary efficacy endpoint was all-cause mortality by Day 42. All-cause mortality on Day 84, overall success (complete + partial response) at end of treatment (EOT) determined by an independent blinded data review committee were recorded. Safety and tolerability were also assessed, as reported by the Investigator.

***Results.*** Overall 412 patients with proven/probable/possible PMD, primarily caused by *Aspergillus* spp. (n = 224), were enrolled. Patient characteristics, outcomes, and adverse events (AEs) are presented in the table. Outcomes in patients with proven/probable cases were similar to those with proven/probable/possible infections.

###### 

Efficacy and safety in patients with PMD

  Parameter                                  ISA (n=200)   VRC (n=212)   Adjusted difference\* % (95% CI)
  ------------------------------------------ ------------- ------------- ----------------------------------
  All-cause mortality on Day 42              34 (17)       44 (21)       −2.9 (−10.4, 4.6)
  All-cause mortality on Day 84              55 (28)       68 (32)       −3.8 (−12.4, 4.8)
  Overall success at EOT                     82 (41)       89 (42)       −1.8 (−11.1, 7.4)
   Complete response                         28 (14)       35 (17)       
   Partial response                          54 (27)       54 (25)       
  Stable                                     53 (27)       60 (28)       
  Progression                                65 (33)       63 (30)       
  *Safety*                                                               P value
   AEs                                       194 (97)      210 (99)      0.2
   Study drug-related AEs                    85 (43)       130 (61)      \<0.001
   Serious AEs                               108 (54)      128 (60)      0.2
   Study drug-related serious AEs            24 (12)       27 (13)       0.9
   AE leading to permanent discontinuation   33 (17)       53 (25)       0.04

\*(ISA--VRC)

***Conclusion.*** ISA had comparable efficacy to VRC for the primary treatment of PMD patients, but had a lower rate of drug-related AEs vs VRC
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